<DOC>
	<DOCNO>NCT02463071</DOCNO>
	<brief_summary>This study randomise , double-blind phase III long-term study evaluate efficacy safety 12 week 52 week AZD0585 administration compare placebo patient hyperlipidemia accompany hypertriglyceridemia .</brief_summary>
	<brief_title>AZD0585 Phase III Long-term Study Japan</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Key Japanese men woman , â‰¥20 year age . Subjects must meet following criterion ; 1 . Fasting triglyceride level : average Visit 2 Visit 3 must range 150 499 mg/dL 2 . % TG change Visit 2 Visit 3 must within 30 % 3 . % LDLC change Visit 2 Visit 3 must within 25 % Key Allergy intolerance omega3 fatty acid omega3acid ethyl ester . Known lipoprotein lipase impairment deficiency , Apolipoprotein CII deficiency familial dysbetalipoproteinemia . Current history pancreatitis . Type I diabetes mellitus , use insulin , haemoglobin A1c &gt; 10 % Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>